Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly prescribed for the management of type 2 DM, congestive heart failure (CHF), and chronic kidney disease (CKD) [12]. Here, SLC5A2 is linked to congestive heart failure.